956034-15-4

Usage

Chemical compound

4-(2-chloro-6-iodothieno[3,2-d]pyrimidin-4-yl)morpholine

Class

Thieno[3,2-d]pyrimidine derivatives

Structure

Contains a morpholine ring attached to a thieno[3,2-d]pyrimidin-4-yl group that is substituted with chlorine at the 2 position and iodine at the 6 position

Potential pharmaceutical applications

Especially in medicinal chemistry and drug discovery

Interesting candidate

For further investigation as a potential drug target for various diseases and disorders

Ongoing research

To explore its biological activities and therapeutic applications

Upstream product

• 16234-15-4 2-chloro-4-morpholinothieno[3,2-d]pyrimidine 
• 113400-36-5 (S)-2-benzyl 1-tert-butyl 5-oxopyrrolidine-1,2-dicarboxylate 
• 16234-14-3 2,4-dichlorothieno[3,2-d]pyrimidine 

Downstream Products

• 1276109-47-7 N₁-(3-(2-acrylamido-5-(4-(2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-1,2,3,6-tetrahydropyridine-1-carbonyl)phenoxy)propyl)-N₅-(15-oxo-19-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)glutaramide 
• 1276109-94-4 N-(2-(3-aminopropoxy)-4-(4-(2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-1,2,3,6-tetrahydropyridine-1-carbonyl)phenyl)acrylamide trifluoroacetate 
• 1276109-92-2 tert-butyl 3-(2-acrylamido-5-(4-(2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-1,2,3,6-tetrahydropyridine-1-carbonyl)phenoxy)propylcarbamate 
• 1276109-64-8 tert-butyl 4-(2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 1033743-48-4 (R)-1-(3-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)phenylthio)propan-2-ol 
• 1033743-34-8 (S)-1-(3-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)phenylthio)propan-2-ol 
• 1033742-91-4 4-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)benzoic acid 
• 1033743-16-6 3-(3-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)phenyl)propan-1-ol 
• 956391-90-5 N-(3-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)phenyl)acetamide 
• 956388-19-5 3-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)benzeneamine 
• 956391-53-0 3-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)benzoic acid 
• 1033743-12-2 1-(3-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)phenyl)ethanone 
• 36926-45-1 4-(2-chloro-6-phenylthieno[3,2-d]pyrimidin-4-yl)morpholine 
• 1033743-21-3 2-chloro-6-(3-(methylsulfonyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidine 

Relevant academic research and scientific papers

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production

LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN

The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.

PI3 KINASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Pharmaceutical compounds

Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE

Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. [Insert Formula Ic and Id]

PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE

Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. Formula (Ic) and (Id).